skip to Main Content
Andrea True Kelly Headshot

Dr. True Kelly began her work at Istari in 2017, bringing with her more than 20 years of combined research and industry experience. Prior to joining Istari, she was Director of Medical Affairs and Clinical Operations with Midatech Pharma US, Inc. Andrea also played a key role in managing clinical programs for both Fuzeon® (enfuvirtide), and the IND filing and first-in-man trial of its next-generation fusion inhibitor, TRI-1144, at Trimeris, Inc. (a Duke spin-out) with Roche. She holds a doctoral degree is in Pharmacology from the University of Illinois College of Medicine in Chicago.

Back To Top
×Close search